高级检索
当前位置: 首页 > 详情页

Overexpressed miR-9 promotes tumor metastasis via targeting E-cadherin in serous ovarian cancer

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE ◇ 统计源期刊 ◇ CSCD-C

单位: [1]Cancer Biology Research Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology,Wuhan 430030, China [2]Wuhan Univ, Zhongnan Hosp, Hubei Key Lab Tumor Biol Behav, Dept Gynecol Oncol,Hubei Canc Clin Study Ctr, Wuhan 430071, Peoples R China [3]Peoples Hosp Shenzhen, Dept Gynecol & Obstet, Shenzhen 518000, Peoples R China
出处:
ISSN:

关键词: ovarian cancer metastasis miR-9 E-cadherin

摘要:
MicroRNAs (miRNAs) play critical roles in the development and progression in various cancers. Dysfunctional miR-9 expression remains ambiguous, and no consensus on the metastatic progression of ovarian cancer has been reached. In this study, results from the bioinformatics analysis show that the 3'-UTR of the E-cadherin mRNA was directly regulated by miR-9. Luciferase reporter assay results confirmed that miR-9 could directly target this 3'-UTR. miR-9 and E-cadherin expression in ovarian cancer tissue was quantified by qRT-PCR. Migration and invasion were detected by wound healing and Transwell system assay in SKOV3 and A2780. qRT-PCR and Western blot were performed to detect the epithelial. mesenchymal transition-associated mRNA and proteins. Immunofluorescence technique was used to analyze the expression and subcellular localization of Ecadherin, N-cadherin, and vimentin. The results showed that miR-9 was frequently upregulated in metastatic serous ovarian cancer tissue compared with paired primary ones. Upregulation of miR-9 could downregulate the expression of E-cadherin but upregulate the expression of mesenchymal markers (N-cadherin and vimentin). Overexpression of miR-9 could promote the cell migration and invasion in ovarian cancer, and these processes could be effectively inhibited via miR-9 inhibitor. Thus, our study demonstrates that miR-9 may promote ovarian cancer metastasis via targeting E-cadherin and a novel potential therapeutic approach to control metastasis of ovarian cancer.

基金:

基金编号: 2015CB553903 81272859 81372801 81230038 81272422 81302266 81402163 81402164 81501530 81572569 Jcyj20140416122811911

语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2016]版:
大类 | 4 区 医学
小类 | 4 区 医学:研究与实验 4 区 肿瘤学
最新[2025]版:
大类 | 2 区 医学
小类 | 2 区 医学:内科 2 区 医学:研究与实验 2 区 肿瘤学
JCR分区:
出版当年[2015]版:
Q3 MEDICINE, RESEARCH & EXPERIMENTAL Q4 ONCOLOGY
最新[2023]版:
Q2 MEDICINE, RESEARCH & EXPERIMENTAL Q2 ONCOLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2015版] 出版当年五年平均 出版前一年[2014版] 出版后一年[2016版]

第一作者:
第一作者单位: [1]Cancer Biology Research Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology,Wuhan 430030, China [2]Wuhan Univ, Zhongnan Hosp, Hubei Key Lab Tumor Biol Behav, Dept Gynecol Oncol,Hubei Canc Clin Study Ctr, Wuhan 430071, Peoples R China
共同第一作者:
通讯作者:
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:426 今日访问量:0 总访问量:408 更新日期:2025-04-01 建议使用谷歌、火狐浏览器 常见问题

版权所有:重庆聚合科技有限公司 渝ICP备12007440号-3 地址:重庆市两江新区泰山大道西段8号坤恩国际商务中心16层(401121)